Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pharmacodynamically-guided, Dose-escalation, Phase I Study to Assess the Safety of AFM11 (Recombinant Antibody Construct Against Human CD19 and CD3) in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL.

NCT02106091 is registered in ClinicalTrials.gov with Affimed GmbH as lead sponsor.

NCT NCT02106091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02106091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pharmacodynamically-guided, Dose-escalation, Phase I Study to Assess the Safety of AFM11 (Recombinant Antibody Construct Against Human CD19 and CD3) in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL.
Lead sponsor
Affimed GmbH
Phase
Phase 1
Overall status
Terminated
Start date
April 30, 2014
Completion date
September 30, 2018
Enrollment
16 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

refractory b-cell non-hodgkin lymphoma, relapsed b-cell non-hodgkin lymphoma